Osage University Partners is among the investors in Northwestern spinout Vanqua Bio’s $85m series B round.

Vanqua Bio, a US-based developer of treatments for neurodegenerative diseases based on research at Northwestern University, emerged yesterday with $85m in series B funding backed by spinout-focused venture capital firm Osage University Partners.
Omega Funds led the round, which also included OrbiMed, Surveyor Capital, Avoro Ventures, Casdin Capital, Pontifax and Logos Capital as well as pharmaceutical firm Eli Lilly.
Founded in 2019 as Surmount Bio, Vanqua Bio is working on therapies that can slow or halt the progression…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
email
Linked in